Retinopathy of Prematurity Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Novartis, Regeneron Pharma, Shire, Bayer, OHB Neonatology

The Key Retinopathy of Prematurity Companies in the market include - Novartis, Regeneron Pharmaceuticals, Shire, Bayer, OHB Neonatology, and others.
DelveInsight's "Retinopathy of Prematurity Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Retinopathy of Prematurity, historical and forecasted epidemiology as well as the Retinopathy of Prematurity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Retinopathy of Prematurity, offering comprehensive insights into the Retinopathy of Prematurity revenue trends, prevalence, and treatment landscape. The report delves into key Retinopathy of Prematurity statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Retinopathy of Prematurity therapies. Additionally, we cover the landscape of Retinopathy of Prematurity clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Retinopathy of Prematurity treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Retinopathy of Prematurity space.

To Know in detail about the Retinopathy of Prematurity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Retinopathy of Prematurity Market Forecast [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Retinopathy of Prematurity Market Report:

*
The Retinopathy of Prematurity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In November 2024, Oak Hill Bio and Chiesi Group have enrolled the first European patient in a Phase IIb clinical trial for their collaborative drug, OHB-607, aimed at preventing bronchopulmonary dysplasia (BPD) in extremely premature infants. The study will also evaluate the drug's effects on weaning from respiratory support by 12 months corrected age, as well as its impact on neurodevelopmental outcomes and the incidence of other complications related to prematurity, including retinopathy of prematurity and intraventricular hemorrhage.

*
The clinical trial for FLQ-101 targeting Retinopathy of Prematurity is expected to begin in the US by 2024.

*
In February 2023, The US FDA has granted approval for EYLEA (aflibercept) injection to treat preterm infants with Retinopathy of Prematurity.

*
Key Retinopathy of Prematurity Companies: Novartis, Regeneron Pharmaceuticals, Shire, Bayer, OHB Neonatology, and others

*
Key Retinopathy of Prematurity Therapies: Ranibizumab, aflibercept, rhIGF-I/rhIGFBP-3, Eylea (Aflibercept, BAY86-5321), OHB-607, and others

*
The Retinopathy of Prematurity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinopathy of Prematurity pipeline products will significantly revolutionize the Retinopathy of Prematurity market dynamics.

*
In 2023, the total number of preterm infant incident cases with a birth weight of less than or equal to 1,500 g in the 7MM was approximately 93,500. These cases are projected to rise throughout the study period from 2020 to 2034.

*
In 2023, approximately 1,700 patients in the US underwent initial treatment for ROP, with around 600 requiring retreatment. In the UK, about 400 patients received initial treatment, while nearly 60 underwent retreatment. Similarly, in Japan, nearly 1,600 patients sought initial treatment for ROP, and approximately 260 required retreatment.

*
In 2023, approximately 24,000 preterm infants in the EU4 with a body weight of less than or equal to 1,500 g were at risk for ROP.

*
According to Guide-Vue.fr (2023), around 30% of premature infants born before 31 weeks of gestation in France and Europe develop retinopathy.

*
In 2023, Germany had the highest number of incident cases of ROP among the EU4, followed by France, while Spain recorded the lowest number of cases.

Retinopathy of Prematurity Overview

Retinopathy of Prematurity (ROP) is a potentially blinding eye disorder that affects premature infants. It occurs when abnormal blood vessels grow and spread in the retina, the light-sensitive layer at the back of the eye. These abnormal vessels can leak or scar, potentially leading to retinal detachment and vision loss.

Get a Free sample for the Retinopathy of Prematurity Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/retinopathy-of-prematurity-market [https://www.delveinsight.com/report-store/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Retinopathy of Prematurity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Retinopathy of Prematurity Epidemiology Segmentation:

The Retinopathy of Prematurity market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Incident Cases of Preterm Infants by Birth Weight ( less than or equal to 1,500g) in the 7MM

*
Total Incident Cases of Retinopathy of Prematurity in the 7MM

*
Total Treated Cases of Retinopathy of Prematurity in the 7MM

Download the report to understand which factors are driving Retinopathy of Prematurity epidemiology trends @ Retinopathy of Prematurity Epidemiology Forecast [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Retinopathy of Prematurity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Retinopathy of Prematurity market or expected to get launched during the study period. The analysis covers Retinopathy of Prematurity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Retinopathy of Prematurity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Retinopathy of Prematurity Therapies and Key Companies

*
Ranibizumab: Novartis

*
aflibercept: Regeneron Pharmaceuticals

*
rhIGF-I/rhIGFBP-3: Shire

*
Eylea (Aflibercept, BAY86-5321): Bayer

*
OHB-607: OHB Neonatology

Discover more about therapies set to grab major Retinopathy of Prematurity market share @ Retinopathy of Prematurity Treatment Landscape [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Retinopathy of Prematurity Market Drivers

*
Rising Prevalence of Premature Births

*
Advancements in Neonatal Care

*
Technological Innovations

*
Government and NGO Support

*
Increasing Healthcare Expenditure

Retinopathy of Prematurity Market Barriers

*
High Treatment Costs

*
Lack of Skilled Professionals

*
Limited Awareness

*
Variability in Guidelines

*
Adverse Treatment Effects

Scope of the Retinopathy of Prematurity Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Retinopathy of Prematurity Companies: Novartis, Regeneron Pharmaceuticals, Shire, Bayer, OHB Neonatology, and others

*
Key Retinopathy of Prematurity Therapies: Ranibizumab, aflibercept, rhIGF-I/rhIGFBP-3, Eylea (Aflibercept, BAY86-5321), OHB-607, and others

*
Retinopathy of Prematurity Therapeutic Assessment: Retinopathy of Prematurity current marketed and Retinopathy of Prematurity emerging therapies

*
Retinopathy of Prematurity Market Dynamics: Retinopathy of Prematurity market drivers and Retinopathy of Prematurity market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Retinopathy of Prematurity Unmet Needs, KOL's views, Analyst's views, Retinopathy of Prematurity Market Access and Reimbursement

To know more about Retinopathy of Prematurity companies working in the treatment market, visit @ Retinopathy of Prematurity Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Retinopathy of Prematurity Market Report Introduction

2. Executive Summary for Retinopathy of Prematurity

3. SWOT analysis of Retinopathy of Prematurity

4. Retinopathy of Prematurity Patient Share (%) Overview at a Glance

5. Retinopathy of Prematurity Market Overview at a Glance

6. Retinopathy of Prematurity Disease Background and Overview

7. Retinopathy of Prematurity Epidemiology and Patient Population

8. Country-Specific Patient Population of Retinopathy of Prematurity

9. Retinopathy of Prematurity Current Treatment and Medical Practices

10. Retinopathy of Prematurity Unmet Needs

11. Retinopathy of Prematurity Emerging Therapies

12. Retinopathy of Prematurity Market Outlook

13. Country-Wise Retinopathy of Prematurity Market Analysis (2020-2034)

14. Retinopathy of Prematurity Market Access and Reimbursement of Therapies

15. Retinopathy of Prematurity Market Drivers

16. Retinopathy of Prematurity Market Barriers

17. Retinopathy of Prematurity Appendix

18. Retinopathy of Prematurity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinopathy-of-prematurity-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-novartis-regeneron-pharma-shire-bayer-ohb-neonatology]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.